Premium
P1‐161: Fractional anisotropy in the evaluation among healthy elderly, amnestic MCI and Alzheimer's disease
Author(s) -
Gang Qi Zhi,
Li Kuncheng
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.05.439
Subject(s) - fractional anisotropy , diffusion mri , medicine , precuneus , gyrus , corpus callosum , white matter , alzheimer's disease , cardiology , nuclear medicine , audiology , psychology , magnetic resonance imaging , pathology , radiology , cognition , disease , psychiatry
a specificity of only 23% in distinguishing it from FTD as most patients with FTD also fulfilled NINCDS-ADRDA criteria for AD. Since pharmacologic treatments differ for AD and FTD, misdiagnosed patients will incur side effects for no benefit with important negative consequences. We present a comprehensive study in discriminating among Alzheimer’s disease, Frontotemporal disease and Healthy Aging (HA) using various biomarkers. Methods: The different biomarkers we compare and contrast are volumes, shape, and surface displacements of both hippocampi and lateral ventricles. The volumes and shape features are computed from the binary segmentations obtained via multi-atlas fusion of the segmentations from a cohort of 30 FTD patients, 34 Probable AD patients and 14 age-matched controls. Results: All the biomarkers are studied in a 3-class setting (AD, FTD and HA) using a fixed classifier to obtain the diagnostic value of these biomarkers in the context of differential diagnosis. To date, such a comprehensive study in a 3-class setting hasn’t been published to the best of our knowledge. Conclusions: A highlight of this study is evidence of high diagnostic value of the ventricular degeneration, in shape and deformation, for the differential diagnosis of FTD, AD and HA. The results present a valuable insight into the discriminative power of different biomarkers studied here and demonstrate the potential of ventricular degeneration as biomarker in the differential diagnosis of FTD, AD and HA.